يعرض 1,681 - 1,700 نتائج من 13,227 نتيجة بحث عن '(( significant increase decrease ) OR ( significant ((linear decrease) OR (greatest decrease)) ))', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1681
  2. 1682
  3. 1683
  4. 1684
  5. 1685
  6. 1686
  7. 1687
  8. 1688

    Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

    منشور في 2024
    الموضوعات:
  9. 1689
  10. 1690
  11. 1691
  12. 1692
  13. 1693
  14. 1694
  15. 1695
  16. 1696

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  17. 1697

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  18. 1698

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  19. 1699
  20. 1700